News
GCVRZ
0.8711
0.00%
0.0000
Trump signs memo to align US child vaccines with certain other countries
Reuters · 2d ago
RPT-TRUMP: CDC VACCINE COMMITTEE MADE A VERY GOOD DECISION TO END THEIR HEPATITIS B VACCINE RECOMMENDATION FOR BABIES
Reuters · 2d ago
Kennedy's vaccine advisers to weigh hepatitis B vaccine timing in consequential policy change
Reuters · 3d ago
Sanofi Completes Acquisition of Vicebio
Reuters · 3d ago
PRESS RELEASE: SANOFI COMPLETES ACQUISITION OF VICEBIO
Reuters · 3d ago
Sanofi and Regeneron win EU approval for Dupixent in chronic spontaneous urticaria
Reuters · 4d ago
BUZZ-Altimmune falls as CEO Vipin Garg to step down
Reuters · 6d ago
Standard Uranium Secures Drill Permits and Launches Gravity Survey at Corvo Project
Reuters · 11/27 12:31
Sanofi and Regeneron win EU approval for Dupixent in chronic spontaneous urticaria
Reuters · 11/25 06:00
SANOFI - DUPIXENT AVAILABLE AS FIRST-LINE TREATMENT FOR CSU
Reuters · 11/25 06:00
COMMUNIQUÉ DE PRESSE : DUPIXENT, DÉVELOPPÉ PAR SANOFI ET REGENERON, A ÉTÉ APPROUVÉ COMME ÉTANT LE PREMIER MÉDICAMENT CIBLÉ DANS L’UE DEPUIS PLUS DE DIX ANS CONTRE L’URTICAIRE CHRONIQUE SPONTANÉE
Reuters · 11/25 06:00
DUPIXENT® (DUPILUMAB) APPROVED AS THE FIRST TARGETED MEDICINE IN THE EUROPEAN UNION (EU) IN OVER A DECADE FOR CHRONIC SPONTANEOUS URTICARIA (CSU)
Reuters · 11/25 06:00
DarioHealth Digital Platform Cuts Hospitalization Rates and Healthcare Costs, Peer-Reviewed Study Finds
Reuters · 11/24 13:01
FDA Grants Priority Review to Sanofi and Regeneron's Dupixent for Allergic Fungal Rhinosinusitis
Reuters · 11/18 17:30
US FDA approves Arrowhead's genetic disorder drug
Reuters · 11/18 16:19
BUZZ-Formycon up after it unveils development of biosimilar candidate for Dupixent
Reuters · 11/17 08:09
Sanofi's type 1 diabetes drug recommended for EU approval
Reuters · 11/14 13:19
BRIEF-EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo
Reuters · 11/14 11:47
BRIEF-EMA Recommends Granting Marketing Authorisation In EU For Teplizumab
Reuters · 11/14 11:45
BRIEF-Press Release Sanofi's Teizeild Recommended For EU Approval By The CHMP For Patients With Stage 2 Type 1 Diabetes
Reuters · 11/14 11:30
More
Webull provides a variety of real-time GCVRZ stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About GCVRZ
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.